Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
January 08, 2024 08:30 ET
|
Neuronetics
MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of...
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
December 18, 2023 08:49 ET
|
Neuronetics
MALVERN, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
December 04, 2023 08:56 ET
|
Neuronetics
MALVERN, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference
November 15, 2023 16:15 ET
|
Neuronetics
MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
November 13, 2023 08:57 ET
|
Neuronetics
MALVERN, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
November 09, 2023 08:32 ET
|
Neuronetics
MALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Third Quarter 2023 Financial and Operating Results
November 07, 2023 07:30 ET
|
Neuronetics
MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2023 16:30 ET
|
Neuronetics
MALVERN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call
October 24, 2023 08:30 ET
|
Neuronetics
MALVERN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes
October 16, 2023 08:56 ET
|
Neuronetics
MALVERN, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...